Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on July 2, 2008
J Am Soc Nephrol 19: 2001-2010, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007121272
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2007121272v1
19/10/2001    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Bao, H.
Right arrow Articles by Li, L.-S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bao, H.
Right arrow Articles by Li, L.-S.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH

Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy

Hao Bao, Zhi-Hong Liu, Hong-Lang Xie, Wei-Xin Hu, Hai-Tao Zhang and Lei-Shi Li

Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Correspondence: Dr. Lei-Shi Li, Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhong Shan Road, Nanjing 210002, China. Phone: 86-25-84801992; Fax: 86-25-84801992; E-mail: lilsh{at}cae.cn

Received for publication December 3, 2007. Accepted for publication April 2, 2008.

Treatment of class V+IV lupus nephritis remains unsatisfactory despite the progress made in the treatment of diffuse proliferative lupus nephritis. In this prospective study, 40 patients with class V+IV lupus nephritis were randomly assigned to induction therapy with mycophenolate mofetil, tacrolimus, and steroids (multitarget therapy) or intravenous cyclophosphamide (IVCY). Patients were treated for 6 mo unless complete remission was not achieved, in which case treatment was extended to 9 mo. An intention-to-treat analysis revealed a higher rate of complete remission with multitarget therapy at both 6 and 9 mo (50 and 65%, respectively) than with IVCY (5 and 15%, respectively). At 6 mo, eight (40%) patients in each group experienced partial remission, and at 9 mo, six (30%) patients receiving multitarget therapy and eight (40%) patients receiving IVCY experienced partial remission. There were no deaths during this study. Most adverse events were less frequent in the multitarget therapy group. Calcineurin inhibitor nephrotoxicity was not observed, but three patients developed new-onset hypertension with multitarget therapy. In conclusion, multitarget therapy is superior to IVCY for inducing complete remission of class V+IV lupus nephritis and is well tolerated.


Related Articles

This Month's Highlights
J. Am. Soc. Nephrol. 2008 19: A6. [Full Text] [PDF]

Multitarget Therapy of Lupus Nephritis: Base Hit or Home Run?
Richard J. Glassock
J. Am. Soc. Nephrol. 2008 19: 1842-1844. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
R. J. Glassock
Multitarget Therapy of Lupus Nephritis: Base Hit or Home Run?
J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1842 - 1844.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673